Document is current

Article History

Received: 15 November 2024

Accepted: 11 February 2025

First Online: 20 March 2025

Declarations

:

: April W. Armstrong has served as a research investigator, scientific advisor, and/or speaker for AbbVie, Almirall, Arcutis, Aslan Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI Health, Incyte, Janssen, Leo Pharma, Lilly, Mindera Health, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB. Leon Kircik has received research grants from AbbVie, Allergan, Almirall, Amgen, Arcutis, Boehringer Ingelheim, Breckinridge Pharma, Bristol Myers Squibb, Celgene, Cellceutix, Centocor, CombiMatrix, Connetics, Coria, Dermavant, Dermira, Dow Pharma, Dr. Reddy’s Laboratories, Galderma, Genentech, GSK, Idera, Johnson & Johnson, Leo Pharma, Lilly, Maruho, Merck, Medicis, Novartis AG, Pfizer, PharmaDerm, Promius, Stiefel, Sun Pharma, UCB, Valeant, and XenoPort, and has received honoraria from AbbVie, Allergan, Almirall, Amgen, Arcutis, Biogen Idec, Bristol Myers Squibb, Celgene, Cipher, Connetics, Dermavant, Dermira, Dr. Reddy’s Laboratories, Galderma, Genentech, GSK, Johnson & Johnson, Leo Pharma, Lilly, Merck, Novartis AG, PharmaDerm, Promius, Serono, Stiefel, Sun Pharma, Taro, UCB, and Valeant. Linda Stein Gold has served as a consultant, advisory board member, and/or speaker for AbbVie, Amgen, Arcutis, Aslan, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Galderma, Incyte, Janssen, Leo Pharma, Lilly, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB. Bruce Strober has served as a consultant with honoraria for AbbVie, Acelyrin, Alamar, Almirall, Alumis, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Bristol Myers Squibb, Capital One, Celltrion, CorEvitas, Dermavant, Inmagene, Janssen/J&J Innovative Medicine, Kangpu Biopharmaceuticals, Leo Pharma, Lilly, Maruho, Meiji Seika Pharma, Monte Rosa Therapeutics, Novartis, Pfizer, Protagonist, RAPT Therapeutics, Regeneron, Sanofi, Sun Pharma, Takeda, TD Cowen, UCB, Union Therapeutics, Ventyx Biosciences, and vTv Therapeutics; as a speaker for AbbVie, Arcutis, Dermavant, Incyte, Janssen/J&J Innovative Medicine, Lilly, Regeneron, and Sanofi; as a co-scientific director (consulting fee) and investigator for the CorEvitas Psoriasis Registry; as editor-in-chief with an honorarium for the Journal of Psoriasis and Psoriatic Arthritis; and holds stock options in Connect Biopharma and Mindera Health. Claudia H. M. C. De Oliveira, John Vaile, Ying-Ming Jou, and Carolin Daamen are employees of and shareholders in Bristol Myers Squibb. Thomas Scharnitz was an employee of and shareholder in Bristol Myers Squibb at the time of study conduct and is now an employee of Novartis. Mark Lebwohl is an employee of Mount Sinai and receives research funds from AbbVie, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Clexio, Dermavant Sciences, Incyte, Inozyme, Janssen, Lilly, Pfizer, Sanofi-Regeneron, and UCB, and is a consultant for Almirall, AltruBio, Apogee, Arcutis, AstraZeneca, Atomwise, Avotres, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, CorEvitas Psoriasis Registry, Dermavant, Dermsquared, Evommune, Facilitation of International Dermatology Education, Forte Biosciences, Galderma, Genentech, Incyte, Leo Pharma, Meiji Seika Pharma, Mindera Health, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. Mark Lebwohl is an Editorial Board member of Dermatology and Therapy. Mark Lebwohl was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

: These studies were conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines of the International Council for Harmonisation and in accordance with the European Union Directive 2001/20/EC and the US Code of Federal Regulations, Title 21, Part 50 (21CFR50), as well as applicable local requirements. The study protocols and amendments were approved by an institutional review board or independent ethics committee before initiation of the study at each site. All patients or their legal representatives provided written informed consent prior to study participation.